Pharmaceuticals, Biotechnology and Life Sciences
“The new funds we are raising will support the ongoing progress of these important assets as well as the rest of our pipeline and we remain very positive about Redx’s prospects.”
Hybrigenics has given an update on the Phase II clinical study of inecalcitol in chronic myeloid leukemia (CML) administered in addition to imatinib, the reference inhibitor of BCR-ABL kinase used as standard of care for CML.
The consumption levels are anticipated to rise exponentially over the forecast period. The companies and government organizations are working collaboratively to bridge the gap between supply and demand.
Forward Pharma has received $ 1.25 billion due to the settlement with Biogen’s subsidiaries, it made in January.
The fourth quarter of 2016, global net sales of Praluent were $41 million, compared to $7 million in the fourth quarter of 2015.
The Global Pulmonary Drug Delivery Devices Market demonstrates a high degree of competition between GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.
Ablynx will present additional data from the Phase IIb RA combination study of its anti-IL-6R Nanobody, vobarilizumab, at the Annual Scientific Meeting of the Canadian Rheumatology Association, being held from 8-11 February 2017 in Ottawa, Ontario (Canada).
Oxford BioTherapeutics has appointed Bernd Seizinger as Chairman, and and Jean-Pierre Bizzari, M.D. as a non-executive director, calling it a significant strengthening of its oncology focused board.
PrEP Biopharm’s study of its drug, earlier confirmed helpful for influenza and human rhinoviruse (HRV), has been undertaken to test its efficacy of the people with asthma, and check for different dosage, showed varying results.
Amryt’s non-executive director Cathal Friel will step down from the board the last day of March 2017, the orphan diseases focused pharmaceutical company said Thursday.